VRRM vs PHVS Comparison

Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe, and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three reportable segments: Commercial Services, Government Solutions, and Parking Solutions. Maximum revenue is generated from the Commercial Services segment, which offers toll and violation management solutions and title and registration services for commercial fleet customers, including RACs and FMCs in North America. In Europe, it provides tolling and violations processing services.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.